GlassScriptPhysician profile
Alexandra Brooks
NPI 1497137756
$9,061.08
in general payments reported to CMS, 2019-2025
28 companies · $1,638 in 2025
The $1,638 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $996 · 2022: $1,364 · 2023: $2,493 · 2024: $2,571 · 2025: $1,638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,222 · Education: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,222.01 |
| Education | $479.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,559.62 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,559.78 | 2022-2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $831.90 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $760.10 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Arcutis Biotherapeutics, INC. | $561.27 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $531.23 | 2022-2024 | Ilumya, Winlevi, Absorica Ld |
| Genzyme Corporation | $443.97 | 2021-2025 | |
| Leo Pharma INC. | $240.88 | 2021-2024 | Adbry |
| Ucb, INC. | $221.30 | 2021-2025 | Bimzelx |
| Incyte Corporation | $180.79 | 2022-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $171.95 | 2021-2024 | |
| Vyne Pharmaceuticals INC. | $150.89 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $130.00 | 2021-2023 | Sotyktu |
| Janssen Scientific Affairs, LLC | $127.73 | 2023 | Tremfya |
| Lilly USA, LLC | $120.10 | 2024-2025 | Ebglyss, Taltz |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $109.34 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $81.95 | 2023-2025 | Cabtreo, Jublia, Siliq |
| Almirall LLC | $44.20 | 2022-2024 | Seysara |
| Amgen INC. | $42.26 | 2022 | |
| Organon LLC | $32.95 | 2025 | Vtama |
| Allergan, INC. | $29.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.75 | 2023 | Cyltezo |
| Mayne Pharma Commercial LLC | $20.03 | 2022-2025 | |
| Strata Skin Sciences, INC. | $19.36 | 2024 | Xtrac |
| Novartis Pharmaceuticals Corporation | $18.68 | 2025 | |
| Biofrontera INC. | $17.83 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Pfizer INC. | $15.27 | 2024 | |
| Epi Health, LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.